Researchers have identified miR-124 signaling and its effects on AMPA receptor neurotransmission as a biological mechanism linking the shared risk scores of schizophrenia and bipolar disorders to their shared symptoms. The work, which appeared online in Neuron on Nov. 14, 2022, focused on schizophrenia and bipolar disorder, which are both highly heritable disorders that share substantial risk. Beyond their implications for those two specific disorders, the findings illustrate a path to connecting risk scores and behaviors via their biological link.
Neurons are specialized cells with a high metabolic demand to fulfill their function, survive or keep a healthy half-life. In this sense, the anabolism and catabolism of proteins and lipids could be associated to different neurodegenerative diseases. At the 2022 annual meeting of the Society for Neuroscience, scientists reported the latest discoveries on neuron metabolic needs at a session on 'Powering Thoughts: The Regulation of Neuronal Energy Metabolism and Mitochondria.'
New and updated preclinical data presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting in Boston, by: Ankyra, Antengene, Artiva, Asher, Bluesphere, Catamaran, Cellectis, Century, Cytoimmune, Domain, Iconovir, Immunitas, Imugene, Imvax, Triumvira Immunologics, Tscan, Umoja.
Eleusis Therapeutics US Inc. has synthesized aryl-ring-substituted 3-phenylazetidines acting as 5-HT2 receptor ligands reported to be useful for the treatment of chronic pain, depression, atherosclerosis, chronic obstructive pulmonary disease, conjunctivitis, type 2 diabetes, multiple sclerosis and rheumatoid arthritis, among others.
RSS
